Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on MoonLake Immunotherapeutics (MLTX – Research Report), Option Care Health (OPCH – Research Report) and FibroGen (FGEN – Research Report).
MoonLake Immunotherapeutics (MLTX)
In a report released today, Julian Harrison from BTIG reiterated a Buy rating on MoonLake Immunotherapeutics, with a price target of $36.00. The company’s shares closed last Monday at $45.95.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
Currently, the analyst consensus on MoonLake Immunotherapeutics is a Strong Buy with an average price target of $51.75, a 2.5% upside from current levels. In a report released today, Guggenheim also maintained a Buy rating on the stock with a $65.00 price target.
See today’s best-performing stocks on TipRanks >>
Option Care Health (OPCH)
In a report released today, Joanna Gajuk from Bank of America Securities reiterated a Buy rating on Option Care Health, with a price target of $38.00. The company’s shares closed last Monday at $31.87.
According to TipRanks.com, Gajuk is a 3-star analyst with an average return of
Currently, the analyst consensus on Option Care Health is a Strong Buy with an average price target of $36.90.
FibroGen (FGEN)
In a report released today, Jason Gerberry from Bank of America Securities downgraded FibroGen to Hold, with a price target of $4.00. The company’s shares closed last Monday at $2.71.
According to TipRanks.com, Gerberry is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for FibroGen with a $10.33 average price target, implying a 223.8% upside from current levels. In a report released today, William Blair also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MLTX:
- MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
- MLTX Skyrockets after Positive Topline Data
- MoonLake announces Phase 2 results for Nanobody sonelokimab in HS
- MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
- MoonLake Immunotherapeutics initiated with an Equal Weight at Barclays
